Drug intelligence / Profile preview

opakalim

Development stage: Phase 3
Lead developer: Biohaven
Modality: Small Molecules
Administration: Oral

Overview

Opakalim (BHV-7000) is a selective small molecule activator of the Kv7.2/Kv7.3 (KCNQ2/KCNQ3) potassium channels. Developed by Biohaven Pharmaceuticals, it is designed to stabilize neuronal membrane potential and reduce hyperexcitability, which is a key driver in seizure activity and mood disorders. The drug is currently in Phase 3 clinical development for focal epilepsy and idiopathic generalized epilepsy. While it was previously evaluated for major depressive disorder (MDD), a Phase 2 study failed to meet its primary endpoint, leading the company to focus its resources on epilepsy and other priority areas such as immunology and obesity.

Other names: opakalim

Targets

KCNQ3 (Potassium voltage-gated channel subfamily Q member 3)KCNQ2 (Potassium voltage-gated channel subfamily KQT member 2)

Beyond the preview

Go deeper on opakalim.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on opakalim.

Explore the full profile